Our studies and those of others have shown that for many normal cell types, stressors that produce DNA damage (such as radiation and chemotherapy) induce a response that includes the robust secretion of specific extracellular effector proteins that we term the DNA Damage Secretory Program (DDSP). The DDSP includes a spectrum of autocrine and paracrine-acting proinflammatory cytokines, proteases and mitogenic growth factors that can promote tumor growth, inhibit cellular differentiation, and enhance angiogenesis. Further, constituents derived from damaged fibroblasts can also induce an epithelial to mesenchymal transition (EMT) in carcinoma cells accompanied by enhanced resistance to chemotherapeutics. Thus, the reaction of any tumor cell to genotoxic stress may depend on both intrinsic damage response capabilities and context dictated by the amalgam of cellular interactions in the tumor microenvironment (TME). In this proposal, we will conduct pre-clinical and clinical trials designed to test the hypothesis that inhibiting components of the microenvironment-derived DNA damage secretory program will enhance the responses of prostate tumors to commonly used genotoxic cancer treatments. We propose two aims:
Aim 1 : To evaluate the effects of inhibiting key regulators and effectors of the microenvironment DNA Damage Secretory Program on therapy responses in preclinical models of prostate cancer. Rationale: defining convergent and divergent influences of master regulators and specific effectors of the microenvironment DDSP will inform pharmacological strategies to maximally inhibit the DDSP, reduce side effects, and improve therapy responses.
Aim 2 : To conduct a Phase l-ll trial evaluating the clinical effect of inhibiting master regulators and specific effectors of the DNA Damage Secretory Program in augmenting genotoxic chemotherapy in men with metastatic CRPC. Rationale: metastatic prostate cancer is essentially incurable. Augmenting chemotherapy responses by suppressing microenvironment resistance mechanisms has the potential to improve therapeutic outcomes produced by commonly used genotoxic chemotherapy.

Public Health Relevance

Metastatic prostate carcinoma is a disease with high lethality, attributable in part to the rapid development of resistance to anti-neoplastic drugs. The successful completion of our studies may alter current concepts of treatment resistance, both to genotoxic and to pathway directed therapeutics, by shifting the emphasis from molecular alterations intrinsic to tumor cells (rare, clonally-selected events) to a context-dependent (genotoxic damage) microenvironment influence on tumor cell phenotypes.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA097186-15
Application #
9336259
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2017-09-01
Budget End
2018-08-31
Support Year
15
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Gomez-Sarosi, Luis; Sun, Yu; Coleman, Ilsa et al. (2017) DNA Damage Induces a Secretory Program in the Quiescent TME that Fosters Adverse Cancer Phenotypes. Mol Cancer Res 15:842-851
Urbanucci, Alfonso; Barfeld, Stefan J; Kytölä, Ville et al. (2017) Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer. Cell Rep 19:2045-2059
Jhun, Min A; Geybels, Milan S; Wright, Jonathan L et al. (2017) Gene expression signature of Gleason score is associated with prostate cancer outcomes in a radical prostatectomy cohort. Oncotarget 8:43035-43047
Nguyen, Holly M; Vessella, Robert L; Morrissey, Colm et al. (2017) LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics. Prostate 77:654-671
Arang, Nadia; Kain, Heather S; Glennon, Elizabeth K et al. (2017) Identifying host regulators and inhibitors of liver stage malaria infection using kinase activity profiles. Nat Commun 8:1232
Lam, Hung-Ming; McMullin, Ryan; Nguyen, Holly M et al. (2017) Characterization of an Abiraterone Ultraresponsive Phenotype in Castration-Resistant Prostate Cancer Patient-Derived Xenografts. Clin Cancer Res 23:2301-2312
Guedes, Liana B; Antonarakis, Emmanuel S; Schweizer, Michael T et al. (2017) MSH2 Loss in Primary Prostate Cancer. Clin Cancer Res 23:6863-6874
Malek, Reem; Gajula, Rajendra P; Williams, Russell D et al. (2017) TWIST1-WDR5-Hottip Regulates Hoxa9 Chromatin to Facilitate Prostate Cancer Metastasis. Cancer Res 77:3181-3193
Green, S M; Kaipainen, A; Bullock, K et al. (2017) Role of OATP transporters in steroid uptake by prostate cancer cells in vivo. Prostate Cancer Prostatic Dis 20:20-27
Lawless, Margaret; Gulati, Roman; Tretiakova, Maria (2017) Stalk versus base invasion in pT1 papillary cancers of the bladder: improved substaging system predicting the risk of progression. Histopathology 71:406-414

Showing the most recent 10 out of 362 publications